
|Articles|March 1, 2002
Greater IOP-lowering effect of drug seen in black population
Memphis, TN-Travoprost 0.004% ophthalmic solution (Travatan, Alcon) is an effective IOP-lowering medication in patients of all racial origins. However, travoprost reduces IOP more in black patients compared with non-black patients, and its efficacy in blacks exceeds that associated with both timolol (Timoptic, Merck) and latanoprost (Xalatan, Pharmacia), said Peter A. Netland, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
2
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
3
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
4
Strategic approaches optimize teaching and learning in the clinic
5












































.png)


